Novavax to supply Switzerland with 6M doses of COVID-19 vaccine

By The Science Advisory Board staff writers

Novavax has agreed to supply the country of Switzerland with 6 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.

The vaccine is currently in phase III clinical development, and is the first to show efficacy against the original COVID-19 strain and the two variants emerging from the U.K. and South Africa, according to the firm.

The company will begin shipping the vaccine to Switzerland after the drug has undergone regulatory review, Novavax said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?